董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joshua Rosensweig | 男 | Director | 64 | 未披露 | 未持股 | 2017-03-30 |
| Brian Markison | 男 | Chairman of the Board of Directors | 57 | 未披露 | 未持股 | 2017-03-30 |
| Gerald Dogon | 男 | External Director | 77 | 未披露 | 未持股 | 2017-03-30 |
| Tali Yaron Eldar | 女 | External Director | 52 | 未披露 | 未持股 | 2017-03-30 |
| David Sidransky | 男 | Director | 55 | 未披露 | 未持股 | 2017-03-30 |
| Roy N. Davis | 男 | Director | 69 | 未披露 | 未持股 | 2017-03-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sigal Russo Gueta | 女 | Senior Director Of Finance | 38 | 未披露 | 未持股 | 2017-03-30 |
| Kenneth A. Berlin | 男 | Chief Executive Officer and President | 52 | 94.41万美元 | 未持股 | 2017-03-30 |
| Ron Kalfus | 男 | Chief Financial Officer | 41 | 26.28万美元 | 未持股 | 2017-03-30 |
| Dganit Bar | 女 | Chief Scientific Officer | 47 | 18.66万美元 | 未持股 | 2017-03-30 |
| Eti Meiri | 女 | Vice President, Research | 47 | 14.96万美元 | 未持股 | 2017-03-30 |
董事简历
中英对照 | 中文 | 英文- Joshua Rosensweig
-
Joshua Rosensweig，2004年5月以来，他是我们董事会的成员。2010年11月以来，他担任Bezeq Israel Telecommunication Corp. Ltd.（以色列的领先的通信集团）、Alrov Real Estate和Hotels Ltd.（一家上市房地产开发公司）的董事会成员。从2003年9月到2006年9月，他担任the First International Bank of Israel的董事长和董事。从1998年到2005年7月，他曾是Gornitzky and Co.（一个专门从事国际交易和税收的律师事务所）的高级合伙人。从1980年到1995年，他在巴伊兰大学的法学院（Bar-Ilan University, Law School）讲课。从1983年到1995年，他在特拉维夫大学（ Tel Aviv University）的商学院讲课。他获得了纽约大学法学院（ New York University Law School）的法学博士（国际税收）和法学硕士（税务）学位。他目前是律师事务所Rosensweig & Aviram, Attorneys的合伙人。
Joshua Rosensweig has served as a member of our board of directors since May 2004. Since November 2010 he has served as a member of the board of directors of Bezeq Israel Telecommunication Corp. Ltd. Israel’s leading communications group and of Alrov Real Estate and Hotels Ltd., a publicly-traded property development company. From September 2003 to September 2006 Dr. Rosensweig served as the Chairman of the Board of Directors of the First International Bank of Israel. From 1998 to July 2005 Dr. Rosensweig was a senior partner at Gornitzky and Co., a law firm where he specialized in international transactions and taxation. Dr. Rosensweig lectured at Bar-Ilan University, Law School from 1980 to 1995 and at Tel Aviv University, School of Business from 1983 to 1995. Dr. Rosensweig received his J.S.D. (International Taxation), and LL.M. (Taxation) from New York University Law School. Dr. Rosensweig is currently a partner at the law firm of Rosensweig & Aviram, Attorneys. - Joshua Rosensweig，2004年5月以来，他是我们董事会的成员。2010年11月以来，他担任Bezeq Israel Telecommunication Corp. Ltd.（以色列的领先的通信集团）、Alrov Real Estate和Hotels Ltd.（一家上市房地产开发公司）的董事会成员。从2003年9月到2006年9月，他担任the First International Bank of Israel的董事长和董事。从1998年到2005年7月，他曾是Gornitzky and Co.（一个专门从事国际交易和税收的律师事务所）的高级合伙人。从1980年到1995年，他在巴伊兰大学的法学院（Bar-Ilan University, Law School）讲课。从1983年到1995年，他在特拉维夫大学（ Tel Aviv University）的商学院讲课。他获得了纽约大学法学院（ New York University Law School）的法学博士（国际税收）和法学硕士（税务）学位。他目前是律师事务所Rosensweig & Aviram, Attorneys的合伙人。
- Joshua Rosensweig has served as a member of our board of directors since May 2004. Since November 2010 he has served as a member of the board of directors of Bezeq Israel Telecommunication Corp. Ltd. Israel’s leading communications group and of Alrov Real Estate and Hotels Ltd., a publicly-traded property development company. From September 2003 to September 2006 Dr. Rosensweig served as the Chairman of the Board of Directors of the First International Bank of Israel. From 1998 to July 2005 Dr. Rosensweig was a senior partner at Gornitzky and Co., a law firm where he specialized in international transactions and taxation. Dr. Rosensweig lectured at Bar-Ilan University, Law School from 1980 to 1995 and at Tel Aviv University, School of Business from 1983 to 1995. Dr. Rosensweig received his J.S.D. (International Taxation), and LL.M. (Taxation) from New York University Law School. Dr. Rosensweig is currently a partner at the law firm of Rosensweig & Aviram, Attorneys.
- Brian Markison
-
Brian Markison，2011年3月以来，他是我们董事会的成员。他被任命在董事会任职来填补由于Berlin先生辞职而空缺的职务。他的任命由股东大会在2011年7月6日通过。2011年4月12日他被任命为董事长。2012年9月以来，他是Avista Capital Partners的医疗行业主管。从2011年7月到2012年7月Fougera Pharmaceuticals Inc.被Novartis的仿制药部门收购，他担任其总裁、首席执行官以及董事会成员。2004年以来，他担任 King Pharmaceuticals的职务。他公司直到2010年被Pfizer以36亿美元收购。此前的1982年到2004年，他曾在百时美施贵宝（Bristol-Myers Squibb）担任各种商业和执行职务，从BMS Oncology/Virology和Oncology Therapeutics Network肿瘤销售代表提拔到总裁。他在Immunomedics, Inc.、PharmAthene Inc.、Lantheus Medical Imaging和Alere Inc的董事会任职，他是Trigen/Vertical的执行主席。他也在新泽西学院（the College of New Jersey）the Komen Foundation的董事会任职。他获得纽约新罗谢尔的爱纳大学 （Iona College）的学士学位。
Brian Markison is the Non-Executive Chairman of the Board and a member of the Science and Technology Committee. Mr. Markison joined the Board in September 2012 and was elevated to Chairman in January 2013. Mr. Markison has been a Healthcare Industry Executive for Avista Capital Partners since September 2012. Mr. Markison is a seasoned executive with more than 30 years of operational, marketing, commercial development and sales experience with international pharmaceutical companies. He is currently Chief Executive Officer and a Director of Osmotica Holdings, S.C.Sp., after serving as Executive Chairman of one of its predecessor companies, Vertical/Trigen Holdings, LLC. Previously, he held the position of President and Chief Executive Officer and member of the Board of Directors of Fougera Pharmaceuticals Inc., a specialty pharmaceutical company in dermatology, prior to its sale to Sandoz, the generics division of Novartis AG. Before leading Fougera, Mr. Markison was Chairman and Chief Executive Officer of King Pharmaceuticals, which he joined as Chief Operating Officer in March 2004 and was promoted to President and Chief Executive Officer later that year and elected Chairman in 2007. Prior to joining King, Mr. Markison held various senior leadership positions at Bristol-Meyers Squibb, including President of Oncology, Virology and Oncology Therapeutics Network; President of Neuroscience, Infectious Disease and Dermatology; and Senior Vice President, Operational Excellence and Productivity. Mr. Markison also serves on the Board of Directors of National Spine Centers LLC and on the Board of Directors of Cosette Pharmaceuticals. He is also a Director of the College of New Jersey. Mr. Markison holds a Bachelor of Science degree from Iona College. - Brian Markison，2011年3月以来，他是我们董事会的成员。他被任命在董事会任职来填补由于Berlin先生辞职而空缺的职务。他的任命由股东大会在2011年7月6日通过。2011年4月12日他被任命为董事长。2012年9月以来，他是Avista Capital Partners的医疗行业主管。从2011年7月到2012年7月Fougera Pharmaceuticals Inc.被Novartis的仿制药部门收购，他担任其总裁、首席执行官以及董事会成员。2004年以来，他担任 King Pharmaceuticals的职务。他公司直到2010年被Pfizer以36亿美元收购。此前的1982年到2004年，他曾在百时美施贵宝（Bristol-Myers Squibb）担任各种商业和执行职务，从BMS Oncology/Virology和Oncology Therapeutics Network肿瘤销售代表提拔到总裁。他在Immunomedics, Inc.、PharmAthene Inc.、Lantheus Medical Imaging和Alere Inc的董事会任职，他是Trigen/Vertical的执行主席。他也在新泽西学院（the College of New Jersey）the Komen Foundation的董事会任职。他获得纽约新罗谢尔的爱纳大学 （Iona College）的学士学位。
- Brian Markison is the Non-Executive Chairman of the Board and a member of the Science and Technology Committee. Mr. Markison joined the Board in September 2012 and was elevated to Chairman in January 2013. Mr. Markison has been a Healthcare Industry Executive for Avista Capital Partners since September 2012. Mr. Markison is a seasoned executive with more than 30 years of operational, marketing, commercial development and sales experience with international pharmaceutical companies. He is currently Chief Executive Officer and a Director of Osmotica Holdings, S.C.Sp., after serving as Executive Chairman of one of its predecessor companies, Vertical/Trigen Holdings, LLC. Previously, he held the position of President and Chief Executive Officer and member of the Board of Directors of Fougera Pharmaceuticals Inc., a specialty pharmaceutical company in dermatology, prior to its sale to Sandoz, the generics division of Novartis AG. Before leading Fougera, Mr. Markison was Chairman and Chief Executive Officer of King Pharmaceuticals, which he joined as Chief Operating Officer in March 2004 and was promoted to President and Chief Executive Officer later that year and elected Chairman in 2007. Prior to joining King, Mr. Markison held various senior leadership positions at Bristol-Meyers Squibb, including President of Oncology, Virology and Oncology Therapeutics Network; President of Neuroscience, Infectious Disease and Dermatology; and Senior Vice President, Operational Excellence and Productivity. Mr. Markison also serves on the Board of Directors of National Spine Centers LLC and on the Board of Directors of Cosette Pharmaceuticals. He is also a Director of the College of New Jersey. Mr. Markison holds a Bachelor of Science degree from Iona College.
- Gerald Dogon
-
Gerald Dogon，2007年2月以来，他是我们董事会的成员。从2004年12月到2006年12月，他担任Scailex Corporation（原名Scailex Corporation）的董事和审计、投资和提名委员会成员。从2005年10月到2006年5月被PMC-Sierra, Inc.收购，他是Passave, Inc.（一个半导体公司）的董事会成员。从1999年到2000年，他担任Nogatech, Inc.的董事和审计委员会的主席。他也是 Fundtech Ltd.的董事会成员和其审计委员会和提名委员会成员。从1994年到1998年，他担任DSPC Inc.的执行副总裁和首席财务官。此外1997年11月到1999年12月，他是其董事会成员。他获得开普敦大学（the University of Cape Town）的经济学士学位。
Gerald Dogon has served as a member of our board of directors since February 2007. From December 2004 to December 2006 Mr. Dogon served as a director and a member of the audit, investment and nomination committees of Scailex Corporation previously Scitex Corporation. From October 2005 until it was acquired by PMC-Sierra, Inc. in May 2006 he served as a member of the board of directors of Passave, Inc., a semiconductor company. From 1999 to 2000 he served as a director and as chairman of the audit committee of Nogatech, Inc. Mr. Dogon has also served as a member of the board of directors of Fundtech Ltd. and was a member of its audit and nominating committees. From 1994 to 1998 Mr. Dogon served as Executive Vice President and Chief Financial Officer of DSPC Inc., and in addition, from November 1997 until December 1999 as a member of its board of directors. Mr. Dogon holds a B.Comm. in Economics from the University of Cape Town. - Gerald Dogon，2007年2月以来，他是我们董事会的成员。从2004年12月到2006年12月，他担任Scailex Corporation（原名Scailex Corporation）的董事和审计、投资和提名委员会成员。从2005年10月到2006年5月被PMC-Sierra, Inc.收购，他是Passave, Inc.（一个半导体公司）的董事会成员。从1999年到2000年，他担任Nogatech, Inc.的董事和审计委员会的主席。他也是 Fundtech Ltd.的董事会成员和其审计委员会和提名委员会成员。从1994年到1998年，他担任DSPC Inc.的执行副总裁和首席财务官。此外1997年11月到1999年12月，他是其董事会成员。他获得开普敦大学（the University of Cape Town）的经济学士学位。
- Gerald Dogon has served as a member of our board of directors since February 2007. From December 2004 to December 2006 Mr. Dogon served as a director and a member of the audit, investment and nomination committees of Scailex Corporation previously Scitex Corporation. From October 2005 until it was acquired by PMC-Sierra, Inc. in May 2006 he served as a member of the board of directors of Passave, Inc., a semiconductor company. From 1999 to 2000 he served as a director and as chairman of the audit committee of Nogatech, Inc. Mr. Dogon has also served as a member of the board of directors of Fundtech Ltd. and was a member of its audit and nominating committees. From 1994 to 1998 Mr. Dogon served as Executive Vice President and Chief Financial Officer of DSPC Inc., and in addition, from November 1997 until December 1999 as a member of its board of directors. Mr. Dogon holds a B.Comm. in Economics from the University of Cape Town.
- Tali Yaron Eldar
-
Tali Yaron Eldar，2007年2月以来，她是我们董事会的成员。2013年1月以来，她担任Yetax law offices的合伙人和创始人。从2007年3月到2012年12月，她担任律师事务所Tadmor & Co。的合伙人。从2004年1月到2007年3月，她曾是律师事务所Cohen, Yaron-Eldar & Co。的合伙人。从2004年1月到2008年1月，她担任Arazim Investment Company的首席执行官。从1998年到2001年，她也担任各种政府职务，包括海关和以色列国家的财政部增值税部门首席法律顾问。从2002年到2004年，她担任以色列的所得税和不动产税务机关的专员。她获得特拉维夫大学（ Tel Aviv University）的财务方向工商管理硕士学位和法学硕士。她是以色列律师协会（ the Israeli Bar Association）的成员。
Tali Yaron Eldar joined our board of directors in January 2020. Ms. Yaron-Eldar is an Israeli attorney specializing in taxation and is the co-founder of Yaron-Eldar, Paller, Schwartz & Co., Law Offices, a boutique firm specializing in tax law. Ms. Yaron-Eldar further serves as a director in various Israeli public companies. From 2004 until 2007 Ms. Yaron-Eldar was a partner at two law offices in Israel. Between January 2004 and January 2008 Ms. Yaron-Eldar served as the Chief Executive Officer of Arazim Investment Company, and from 1998 until 2004 also served in various senior roles in the Israeli Tax Authority, including as the Commissioner of Income Tax and Real Property Tax Authority of the State of Israel for a period of two years. Ms. Yaron-Eldar holds an LL.B. degree from Tel Aviv University and an M.B.A. specializing in finance from Tel Aviv University. Ms. Yaron-Eldar is also a member of the Israeli Bar Association. - Tali Yaron Eldar，2007年2月以来，她是我们董事会的成员。2013年1月以来，她担任Yetax law offices的合伙人和创始人。从2007年3月到2012年12月，她担任律师事务所Tadmor & Co。的合伙人。从2004年1月到2007年3月，她曾是律师事务所Cohen, Yaron-Eldar & Co。的合伙人。从2004年1月到2008年1月，她担任Arazim Investment Company的首席执行官。从1998年到2001年，她也担任各种政府职务，包括海关和以色列国家的财政部增值税部门首席法律顾问。从2002年到2004年，她担任以色列的所得税和不动产税务机关的专员。她获得特拉维夫大学（ Tel Aviv University）的财务方向工商管理硕士学位和法学硕士。她是以色列律师协会（ the Israeli Bar Association）的成员。
- Tali Yaron Eldar joined our board of directors in January 2020. Ms. Yaron-Eldar is an Israeli attorney specializing in taxation and is the co-founder of Yaron-Eldar, Paller, Schwartz & Co., Law Offices, a boutique firm specializing in tax law. Ms. Yaron-Eldar further serves as a director in various Israeli public companies. From 2004 until 2007 Ms. Yaron-Eldar was a partner at two law offices in Israel. Between January 2004 and January 2008 Ms. Yaron-Eldar served as the Chief Executive Officer of Arazim Investment Company, and from 1998 until 2004 also served in various senior roles in the Israeli Tax Authority, including as the Commissioner of Income Tax and Real Property Tax Authority of the State of Israel for a period of two years. Ms. Yaron-Eldar holds an LL.B. degree from Tel Aviv University and an M.B.A. specializing in finance from Tel Aviv University. Ms. Yaron-Eldar is also a member of the Israeli Bar Association.
- David Sidransky
-
David Sidransky博士，目前担任约翰·霍普金斯大学头颈部癌症研究部主任、耳鼻喉科—头颈部外科教授、细胞与分子医学教授以及泌尿科及遗传学教授。Sidransky博士目前亦担任约翰霍普金斯肿瘤中心的肿瘤科教授。从1984年至1988年，Sidransky博士在美国贝勒大学医学院工作，并取得其医学博士学位，随后继续担任内科实习生及驻院医生，及担任内科首席驻院医生直至1988年6月。从1988年7月至1992年6月，Sidransky博士在约翰·霍普金斯大学及医院完成肿瘤科研究生课程，随后于1992年7月获委任为教师。Sidransky博士于1981年6月毕业于美国布兰迪斯大学，获得化学理学士学位。Sidransky博士是美国癌症研究协会及美国临床肿瘤学协会的现任会员。彼曾为美国国家癌症研究所下属多个工作组（包括发展诊断工作组及癌症预防及控制工作组）的成员。Sidransky博士亦获得美国内科医学委员会及美国肿瘤医学委员会的认证。此外，Sidransky博士目前参与美国国家癌症研究所国家科学顾问委员会。彼为Champions Oncology, Inc.（纳斯达克：CSBR）的创始人，目前为董事会领导。彼为Galmed Pharmaceuticals Ltd.（纳斯达克：GLMD）董事、Orgenesis Inc.（纳斯达克：ORGS）董事、Advaxis, Inc.（纳斯达克：ADXS）主席及Ayala Pharmaceuticals, Inc.（纳斯达克：AYLA）主席。彼亦为空服员医学研究基金会（Flight Attendants Medical Research Foundation）及囊癌研究（Adenocystic Carcinoma Research）的MAB主席。Sidransky博士获得了许多荣誉，如以色列癌症研究基金奥瑟曼奖（Israel Cancer Research Fund Osserman Award）、AACR — Richardand Hinda Rosenthal Foundation Award、巴伊兰大学杜比高密奖（Toby Comet Award Bar Ilan University）及AACR Team Award Theme Circulating DNA。截至本公告日期，彼于专业期刊上曾发表逾550篇文章、撰写45篇书籍章节、评述及评论以及为28项专利的发明者。于2021年3月31日获委任为亚盛医药集团独立非执行董事。
David Sidransky,has served as Lead Director of the Company since November 2016. Previously, Dr. Sidransky served as the Chairman of the Company from October 2007 to November 2016 and has served as a director of the Company since August 2007. Dr. Sidransky is a Professor of Oncology, Otolaryngology-Head and Neck Surgery, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at Johns Hopkins University and Hospital. In the field of oncology, Dr. Sidransky is one of the most highly-cited researchers in clinical and medical journals in the world, with over 600 peer-reviewed publications in the past decade. He has also contributed to more than 60 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has served as Vice Chairman of the Board of Directors of ImClone Systems, Inc., a global biopharmaceutical company committed to advancing oncology care, and was a director, until its merger with Eli Lilly. Dr. Sidransky is Chairman of the Board of Ayala Pharmaceuticals and Advaxis Immunotherapies and serves on the board of directors of Galmed, Ascentage, and Orgenesis. From 2005 to 2008, Dr. Sidransky served as Director of the American Association for Cancer Research (AACR). Dr. Sidransky is the recipient of many awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, the 2004 Hinda and Richard Rosenthal Award for innovative research and the 2017 team award from the AACR for the development of circulating DNA testing. Dr. Sidransky is certified in Internal Medicine and Medical Oncology by the American Board of Medicine. Dr. Sidransky received his bachelor's degree from Brandeis University and his medical degree from the Baylor College of Medicine. - David Sidransky博士，目前担任约翰·霍普金斯大学头颈部癌症研究部主任、耳鼻喉科—头颈部外科教授、细胞与分子医学教授以及泌尿科及遗传学教授。Sidransky博士目前亦担任约翰霍普金斯肿瘤中心的肿瘤科教授。从1984年至1988年，Sidransky博士在美国贝勒大学医学院工作，并取得其医学博士学位，随后继续担任内科实习生及驻院医生，及担任内科首席驻院医生直至1988年6月。从1988年7月至1992年6月，Sidransky博士在约翰·霍普金斯大学及医院完成肿瘤科研究生课程，随后于1992年7月获委任为教师。Sidransky博士于1981年6月毕业于美国布兰迪斯大学，获得化学理学士学位。Sidransky博士是美国癌症研究协会及美国临床肿瘤学协会的现任会员。彼曾为美国国家癌症研究所下属多个工作组（包括发展诊断工作组及癌症预防及控制工作组）的成员。Sidransky博士亦获得美国内科医学委员会及美国肿瘤医学委员会的认证。此外，Sidransky博士目前参与美国国家癌症研究所国家科学顾问委员会。彼为Champions Oncology, Inc.（纳斯达克：CSBR）的创始人，目前为董事会领导。彼为Galmed Pharmaceuticals Ltd.（纳斯达克：GLMD）董事、Orgenesis Inc.（纳斯达克：ORGS）董事、Advaxis, Inc.（纳斯达克：ADXS）主席及Ayala Pharmaceuticals, Inc.（纳斯达克：AYLA）主席。彼亦为空服员医学研究基金会（Flight Attendants Medical Research Foundation）及囊癌研究（Adenocystic Carcinoma Research）的MAB主席。Sidransky博士获得了许多荣誉，如以色列癌症研究基金奥瑟曼奖（Israel Cancer Research Fund Osserman Award）、AACR — Richardand Hinda Rosenthal Foundation Award、巴伊兰大学杜比高密奖（Toby Comet Award Bar Ilan University）及AACR Team Award Theme Circulating DNA。截至本公告日期，彼于专业期刊上曾发表逾550篇文章、撰写45篇书籍章节、评述及评论以及为28项专利的发明者。于2021年3月31日获委任为亚盛医药集团独立非执行董事。
- David Sidransky,has served as Lead Director of the Company since November 2016. Previously, Dr. Sidransky served as the Chairman of the Company from October 2007 to November 2016 and has served as a director of the Company since August 2007. Dr. Sidransky is a Professor of Oncology, Otolaryngology-Head and Neck Surgery, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at Johns Hopkins University and Hospital. In the field of oncology, Dr. Sidransky is one of the most highly-cited researchers in clinical and medical journals in the world, with over 600 peer-reviewed publications in the past decade. He has also contributed to more than 60 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has served as Vice Chairman of the Board of Directors of ImClone Systems, Inc., a global biopharmaceutical company committed to advancing oncology care, and was a director, until its merger with Eli Lilly. Dr. Sidransky is Chairman of the Board of Ayala Pharmaceuticals and Advaxis Immunotherapies and serves on the board of directors of Galmed, Ascentage, and Orgenesis. From 2005 to 2008, Dr. Sidransky served as Director of the American Association for Cancer Research (AACR). Dr. Sidransky is the recipient of many awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, the 2004 Hinda and Richard Rosenthal Award for innovative research and the 2017 team award from the AACR for the development of circulating DNA testing. Dr. Sidransky is certified in Internal Medicine and Medical Oncology by the American Board of Medicine. Dr. Sidransky received his bachelor's degree from Brandeis University and his medical degree from the Baylor College of Medicine.
- Roy N. Davis
-
Roy N. Davis，2012年6月以来，他是我们董事会的成员。他于1984年加入强生公司（Johnson & Johnson ）。在2012年1月退休之前，他担任27年美国、欧洲和亚洲该公司的组织的领导职务并不断被提拔。从2008年1月到2012年1月，他担任J&J Development Corporation（强生公司（Johnson & Johnson ）的独资企业部门）和所有强生公司（Johnson & Johnson ）的公司发展副总裁。在担任这些职务时，他负责目前强生业务部门以外地区的收购和许可以及代表强生公司（J&J）进行风险资本投资和管理其全资子公司。这些努力集中在强生公司（J&J）的新公司拓展为其提供转型医疗解决方案。从2003年到2007年，他担任庆生的公司部门主席和奥托临床诊断（ Ortho-Clinical Diagnostics）全球经销权主席负责Ortho Clinical Diagnostics, Inc.、Veridex LLC和Therakos, Inc.。他获得纽约州立大学（the State University of New York）的学士学位和伦斯勒理工学院（Rensselaer Polytechnic Institute）的硕士学位。他目前是克里夫兰医疗中心（The Cleveland Clinic）的咨询委员会和the Wake Forest Institute for Regenerative Medicine的咨询委员会的成员。2012年3月他被任命在Innosight（一个创新咨询公司）的董事会任职。
Roy N. Davis has served as a member of our board of directors since June 2012. Mr. Davis joined Johnson & Johnson J&J in 1984 where he moved through leadership positions of increasing responsibility in the organization in the U.S., Europe and Asia for 27 years prior to his retirement in January 2012. Most recently, from January 2008 through January 2012 Mr. Davis was President, J&J Development Corporation, J&J’s wholly owned venture group, and Vice President of Corporate Development for all of J&J. In these roles Mr. Davis was responsible for acquisition and licensing in areas outside of current J&J business sectors, venture capital investing on behalf of J&J and management of J&J’s wholly owned ventures. These efforts focused on developing new companies for J&J that offer transformational health care solutions. From 2003 to 2007 Mr. Davis held the positions of Company Group Chairman, J&J and Worldwide Franchise Chairman, Ortho Clinical Diagnostics with responsibilities for Ortho Clinical Diagnostics, Inc., Veridex LLC and Therakos, Inc. Mr. Davis received a Bachelor of Science from the State University of New York and a Master of Science from Rensselaer Polytechnic Institute. He served as a member of the Innovations Advisory Board for the Cleveland Clinic during 2008-2014 and is currently a member of the Advisory Board for the Wake Forest Institute for Regenerative Medicine and in March 2012 was named to the Board of Directors of Innosight, an innovation consulting firm. - Roy N. Davis，2012年6月以来，他是我们董事会的成员。他于1984年加入强生公司（Johnson & Johnson ）。在2012年1月退休之前，他担任27年美国、欧洲和亚洲该公司的组织的领导职务并不断被提拔。从2008年1月到2012年1月，他担任J&J Development Corporation（强生公司（Johnson & Johnson ）的独资企业部门）和所有强生公司（Johnson & Johnson ）的公司发展副总裁。在担任这些职务时，他负责目前强生业务部门以外地区的收购和许可以及代表强生公司（J&J）进行风险资本投资和管理其全资子公司。这些努力集中在强生公司（J&J）的新公司拓展为其提供转型医疗解决方案。从2003年到2007年，他担任庆生的公司部门主席和奥托临床诊断（ Ortho-Clinical Diagnostics）全球经销权主席负责Ortho Clinical Diagnostics, Inc.、Veridex LLC和Therakos, Inc.。他获得纽约州立大学（the State University of New York）的学士学位和伦斯勒理工学院（Rensselaer Polytechnic Institute）的硕士学位。他目前是克里夫兰医疗中心（The Cleveland Clinic）的咨询委员会和the Wake Forest Institute for Regenerative Medicine的咨询委员会的成员。2012年3月他被任命在Innosight（一个创新咨询公司）的董事会任职。
- Roy N. Davis has served as a member of our board of directors since June 2012. Mr. Davis joined Johnson & Johnson J&J in 1984 where he moved through leadership positions of increasing responsibility in the organization in the U.S., Europe and Asia for 27 years prior to his retirement in January 2012. Most recently, from January 2008 through January 2012 Mr. Davis was President, J&J Development Corporation, J&J’s wholly owned venture group, and Vice President of Corporate Development for all of J&J. In these roles Mr. Davis was responsible for acquisition and licensing in areas outside of current J&J business sectors, venture capital investing on behalf of J&J and management of J&J’s wholly owned ventures. These efforts focused on developing new companies for J&J that offer transformational health care solutions. From 2003 to 2007 Mr. Davis held the positions of Company Group Chairman, J&J and Worldwide Franchise Chairman, Ortho Clinical Diagnostics with responsibilities for Ortho Clinical Diagnostics, Inc., Veridex LLC and Therakos, Inc. Mr. Davis received a Bachelor of Science from the State University of New York and a Master of Science from Rensselaer Polytechnic Institute. He served as a member of the Innovations Advisory Board for the Cleveland Clinic during 2008-2014 and is currently a member of the Advisory Board for the Wake Forest Institute for Regenerative Medicine and in March 2012 was named to the Board of Directors of Innosight, an innovation consulting firm.
高管简历
中英对照 | 中文 | 英文- Sigal Russo Gueta
Sigal Russo Gueta，2008年9月加入Rosetta，成为我们的执行官。2004年到2008年，她在以色列的Ernst & Young担任审计经理，负责公司各方面的审计，包括美国和以色列的上市和私有团体。她拥有鲁宾学院经济学和会计学学士学位，并成为以色列的一名注册会计师。
Sigal Russo Gueta joined us in September 2008 as our controller. Prior to joining Rosetta, Ms. Russo worked as an audit manager at Ernst & Young in Israel, specializing in audits of companies from various fields, both publicly traded and privately owned American and Israeli entities, from 2004 to 2008. Ms. Russo holds a BA in economics and accounting, from the Ruppin Academic College, and is a Certified Public Accountant licensed in Israel.- Sigal Russo Gueta，2008年9月加入Rosetta，成为我们的执行官。2004年到2008年，她在以色列的Ernst & Young担任审计经理，负责公司各方面的审计，包括美国和以色列的上市和私有团体。她拥有鲁宾学院经济学和会计学学士学位，并成为以色列的一名注册会计师。
- Sigal Russo Gueta joined us in September 2008 as our controller. Prior to joining Rosetta, Ms. Russo worked as an audit manager at Ernst & Young in Israel, specializing in audits of companies from various fields, both publicly traded and privately owned American and Israeli entities, from 2004 to 2008. Ms. Russo holds a BA in economics and accounting, from the Ruppin Academic College, and is a Certified Public Accountant licensed in Israel.
- Kenneth A. Berlin
Kenneth A. Berlin，他于2009年11月加入我们并担任我们的总裁兼首席执行官。2009年12月他被任命为我们的股东并且是我们董事会成员。2011年3月辞去董事职务。在加入我们之前，他担任cellular and molecular cancer diagnostics developer Veridex, LLC（一个强生公司（ Johnson & Johnson））的全球总经理。在他的领导下，组织增长到超过100名员工。他率先推出三个癌症诊断产品、收购其细胞诊断合伙人并且在Veridex由一个研发实体到肿瘤诊断的产品和服务的供应商的转型中获得显著增长。在他任职期间，他获得许多奖项，包括由于对抗癌症中应用其创新的CellSearch technology获得克里夫兰医疗中心（The Cleveland Clinic）和Prix Galien的认可。他于1994年加入强生公司（Johnson & Johnson ）并担任了6年的公司顾问。他担任强生公司（Johnson & Johnson ）和许多其子公司的各种职务并不断被提拔。从2001年到2004年，他担任药品部门的副总裁负责许可和新业务开发。从2004年到2007年，他曾是奥托临床诊断（ Ortho-Clinical Diagnostics）国际副总裁负责财务发展。他获得普林斯顿大学（Princeton University）的学士学位和加州大学（University of California）洛杉矶法学院的的法学博士学位。
Kenneth A. Berlin joined us in November 2009 as our President and Chief Executive Officer. He was later appointed by our shareholders in December 2009 as a member of our board of directors, and resigned as a director in March 2011. Prior to joining us, Mr. Berlin, served as Worldwide General Manager at cellular and molecular cancer diagnostics developer Veridex, LLC, a Johnson & Johnson company. Under his leadership the organization grew to over 100 employees, and he spearheaded the launch of three cancer diagnostic products, the acquisition of its cellular diagnostics partner, and delivered significant growth in sales as Veridex transitioned from a research and development entity to a commercial provider of oncology diagnostic products and services. During Mr. Berlin’s tenure, Veridex received numerous awards including recognition from the Cleveland Clinic and Prix Galien for the use of its innovative CellSearch® technology in the fight against cancer. Mr. Berlin joined Johnson & Johnson in 1994 and served as corporate counsel for six years. He then held positions of increasing responsibility within Johnson & Johnson and a number of its subsidiary companies. From 2001 until 2004 he served as Vice President, licensing and new business development in the pharmaceuticals group, and from 2004 until 2007 was Worldwide Vice President, franchise development, Ortho-Clinical Diagnostics. Mr. Berlin holds an A.B. degree from Princeton University and a J.D. from the University of California, Los Angeles School of Law.- Kenneth A. Berlin，他于2009年11月加入我们并担任我们的总裁兼首席执行官。2009年12月他被任命为我们的股东并且是我们董事会成员。2011年3月辞去董事职务。在加入我们之前，他担任cellular and molecular cancer diagnostics developer Veridex, LLC（一个强生公司（ Johnson & Johnson））的全球总经理。在他的领导下，组织增长到超过100名员工。他率先推出三个癌症诊断产品、收购其细胞诊断合伙人并且在Veridex由一个研发实体到肿瘤诊断的产品和服务的供应商的转型中获得显著增长。在他任职期间，他获得许多奖项，包括由于对抗癌症中应用其创新的CellSearch technology获得克里夫兰医疗中心（The Cleveland Clinic）和Prix Galien的认可。他于1994年加入强生公司（Johnson & Johnson ）并担任了6年的公司顾问。他担任强生公司（Johnson & Johnson ）和许多其子公司的各种职务并不断被提拔。从2001年到2004年，他担任药品部门的副总裁负责许可和新业务开发。从2004年到2007年，他曾是奥托临床诊断（ Ortho-Clinical Diagnostics）国际副总裁负责财务发展。他获得普林斯顿大学（Princeton University）的学士学位和加州大学（University of California）洛杉矶法学院的的法学博士学位。
- Kenneth A. Berlin joined us in November 2009 as our President and Chief Executive Officer. He was later appointed by our shareholders in December 2009 as a member of our board of directors, and resigned as a director in March 2011. Prior to joining us, Mr. Berlin, served as Worldwide General Manager at cellular and molecular cancer diagnostics developer Veridex, LLC, a Johnson & Johnson company. Under his leadership the organization grew to over 100 employees, and he spearheaded the launch of three cancer diagnostic products, the acquisition of its cellular diagnostics partner, and delivered significant growth in sales as Veridex transitioned from a research and development entity to a commercial provider of oncology diagnostic products and services. During Mr. Berlin’s tenure, Veridex received numerous awards including recognition from the Cleveland Clinic and Prix Galien for the use of its innovative CellSearch® technology in the fight against cancer. Mr. Berlin joined Johnson & Johnson in 1994 and served as corporate counsel for six years. He then held positions of increasing responsibility within Johnson & Johnson and a number of its subsidiary companies. From 2001 until 2004 he served as Vice President, licensing and new business development in the pharmaceuticals group, and from 2004 until 2007 was Worldwide Vice President, franchise development, Ortho-Clinical Diagnostics. Mr. Berlin holds an A.B. degree from Princeton University and a J.D. from the University of California, Los Angeles School of Law.
- Ron Kalfus
Ron Kalfus，他于2012年5月加入我们并担任我们的首席财务官。在加入 Rosetta之前的2008年到2012年，他担任MabCure Inc.（一个早期癌症检测使用抗体的上市生物技术创业公司）的首席财务官和司库。从2003年到2007年，他担任Toys “R” Us, Inc.的各种职务，负责公司的证券交易委员会（the Securities and Exchange Commission）的财务报告和the Toys “R” Us division的度预算。在加入Toys “R” Us, Inc.之前，他在两个面向中型企业和上市公司的审计和大型上市会计公司担任审计员。他持有费尔里·狄金生大学（Fairleigh Dickinson University）的会计学士学位，以及西乔治亚大学（the University of West Georgia）的财务方向工商管理学士学位。
Ron Kalfus,our chief financial officer, joined MDxHealth in July 2019. He has over 20 years of leadership experience in both public and private companies within diagnostics/biotech and other sectors. Mr. Kalfus joined MDxHealth from Rosetta Genomics, where he helped lead efforts to reposition the company for commercial success with its oncology diagnostic products. Prior to Rosetta, Mr. Kalfus served as the CFO and Treasurer of MabCure, a Belgium-based publicly-traded biotechnology start up in the field of early cancer detection using antibodies. Mr. Kalfus holds a MS in Accounting from Fairleigh Dickinson University and a BBA in Finance from the University of Georgia and is a CPA licensed in New Jersey.- Ron Kalfus，他于2012年5月加入我们并担任我们的首席财务官。在加入 Rosetta之前的2008年到2012年，他担任MabCure Inc.（一个早期癌症检测使用抗体的上市生物技术创业公司）的首席财务官和司库。从2003年到2007年，他担任Toys “R” Us, Inc.的各种职务，负责公司的证券交易委员会（the Securities and Exchange Commission）的财务报告和the Toys “R” Us division的度预算。在加入Toys “R” Us, Inc.之前，他在两个面向中型企业和上市公司的审计和大型上市会计公司担任审计员。他持有费尔里·狄金生大学（Fairleigh Dickinson University）的会计学士学位，以及西乔治亚大学（the University of West Georgia）的财务方向工商管理学士学位。
- Ron Kalfus,our chief financial officer, joined MDxHealth in July 2019. He has over 20 years of leadership experience in both public and private companies within diagnostics/biotech and other sectors. Mr. Kalfus joined MDxHealth from Rosetta Genomics, where he helped lead efforts to reposition the company for commercial success with its oncology diagnostic products. Prior to Rosetta, Mr. Kalfus served as the CFO and Treasurer of MabCure, a Belgium-based publicly-traded biotechnology start up in the field of early cancer detection using antibodies. Mr. Kalfus holds a MS in Accounting from Fairleigh Dickinson University and a BBA in Finance from the University of Georgia and is a CPA licensed in New Jersey.
- Dganit Bar
Dganit Bar，她于2012年10月加入我们并担任首席科学官。她加入Rosetta时就有10多年的药物开发经验。在加入Rosetta之前的2004年到2012年，她担任BioLineRx, Ltd（生物制药公司）各种职务，包括科技执行董事负责跨越不同的治疗领域包括肿瘤学、心血管和中枢神经系统的候选药物的开发和许可。从2000年到2004年，她曾在QBI Enterprises, Ltd任职。她担任的几个职务包括公司肿瘤学管道的癌症研究负责人。她获得耶路撒冷的希伯来大学（The Hebrew University）的生命科学学士学位。她获得内盖夫的班古里昂大学（Ben-Gurion University）的生物技术硕士学位和生物工程博士学位。
Dganit Bar joined Rosetta Genomics Ltd. in October 2012 as Rosetta Genomics Ltd. Chief Scientific Officer.Prior to joining Rosetta, from 2004 to 2012 she served in various positions, including Executive Director Science & Technology at BioLineRx, Ltd, a biopharmaceutical company, where she led the development and out-licensing of several drug candidates spanning different therapeutic areas, including oncology, cardiovascular and CNS. From 2000 to 2004 Dr. Bar was with QBI Enterprises, Ltd, where she held several positions including Head of Cancer Research working on the company's oncology pipeline. Dr. Bar received her B.Sc. in Life Science from The Hebrew University, Jerusalem. She holds an M.Sc. in Biotechnology and a Ph.D. in Biotechnology Engineering from Ben-Gurion University of the Negev.- Dganit Bar，她于2012年10月加入我们并担任首席科学官。她加入Rosetta时就有10多年的药物开发经验。在加入Rosetta之前的2004年到2012年，她担任BioLineRx, Ltd（生物制药公司）各种职务，包括科技执行董事负责跨越不同的治疗领域包括肿瘤学、心血管和中枢神经系统的候选药物的开发和许可。从2000年到2004年，她曾在QBI Enterprises, Ltd任职。她担任的几个职务包括公司肿瘤学管道的癌症研究负责人。她获得耶路撒冷的希伯来大学（The Hebrew University）的生命科学学士学位。她获得内盖夫的班古里昂大学（Ben-Gurion University）的生物技术硕士学位和生物工程博士学位。
- Dganit Bar joined Rosetta Genomics Ltd. in October 2012 as Rosetta Genomics Ltd. Chief Scientific Officer.Prior to joining Rosetta, from 2004 to 2012 she served in various positions, including Executive Director Science & Technology at BioLineRx, Ltd, a biopharmaceutical company, where she led the development and out-licensing of several drug candidates spanning different therapeutic areas, including oncology, cardiovascular and CNS. From 2000 to 2004 Dr. Bar was with QBI Enterprises, Ltd, where she held several positions including Head of Cancer Research working on the company's oncology pipeline. Dr. Bar received her B.Sc. in Life Science from The Hebrew University, Jerusalem. She holds an M.Sc. in Biotechnology and a Ph.D. in Biotechnology Engineering from Ben-Gurion University of the Negev.
- Eti Meiri
Eti Meiri, Ph.D.，2012年5月以来，她担任我们的副总裁负责研究。2003年以来，她曾担任我们的高级分子生物学研究员。 她为我们的科学做出了贡献并对这些年来所有的研发活动用帮助。她的贡献包括微RNA数组的平台（microRNA array platform）的发展和临床样本抽取的微RNA的RNA提取协议的发展。在加入我们之前的2001年到2002年，她担任ViroGene Ltd的高级研究员。她是同行评审期刊的20篇发表的论文的作者。她获得雷霍沃特的以色列魏兹曼科学院（the Weizmann Institute of Science）的植物科学系的哲学博士学位、耶路撒冷希伯来大学（The Hebrew university of Jerusalem）的硕士学位和特拉维夫大学（ Tel Aviv University）生命科学学院的学士学位。
Eti Meiri has served as our Vice President, Research since May 2012. She previously served as our Senior Scientist, Molecular Biology since 2003. Her contributions included the development of our microRNA array platform as well as the development of RNA extraction protocols suitable for microRNA extraction from clinical samples. Prior to joining us, from 2001 to 2002 Dr. Meiri served as Senior Scientist in ViroGene Ltd. She is the author of 20 papers published in peer reviewed journals. Dr. Meiri earned her Ph.D. from the Department of Plant Sciences in the Weizmann Institute of Science in Rehovot, her M.Sc. from The Hebrew University of Jerusalem, and her B.Sc. from the faculty of life sciences, in Tel Aviv University.- Eti Meiri, Ph.D.，2012年5月以来，她担任我们的副总裁负责研究。2003年以来，她曾担任我们的高级分子生物学研究员。 她为我们的科学做出了贡献并对这些年来所有的研发活动用帮助。她的贡献包括微RNA数组的平台（microRNA array platform）的发展和临床样本抽取的微RNA的RNA提取协议的发展。在加入我们之前的2001年到2002年，她担任ViroGene Ltd的高级研究员。她是同行评审期刊的20篇发表的论文的作者。她获得雷霍沃特的以色列魏兹曼科学院（the Weizmann Institute of Science）的植物科学系的哲学博士学位、耶路撒冷希伯来大学（The Hebrew university of Jerusalem）的硕士学位和特拉维夫大学（ Tel Aviv University）生命科学学院的学士学位。
- Eti Meiri has served as our Vice President, Research since May 2012. She previously served as our Senior Scientist, Molecular Biology since 2003. Her contributions included the development of our microRNA array platform as well as the development of RNA extraction protocols suitable for microRNA extraction from clinical samples. Prior to joining us, from 2001 to 2002 Dr. Meiri served as Senior Scientist in ViroGene Ltd. She is the author of 20 papers published in peer reviewed journals. Dr. Meiri earned her Ph.D. from the Department of Plant Sciences in the Weizmann Institute of Science in Rehovot, her M.Sc. from The Hebrew University of Jerusalem, and her B.Sc. from the faculty of life sciences, in Tel Aviv University.